Close Menu

NEW YORK (GenomeWeb) – Great Basin Scientific today announced it has submitted its Shiga Toxin Direct Test to the US Food and Drug Administration for 510(k) review. 

The submission follows the successful completion of a clinical trial by the Salt Lake City-based firm that met all of its clinical objectives, Great Basin said. If cleared, the test will be the only stand-alone molecular test for detecting Shiga toxin-producing E. coli and the serotype O157 directly from a patient specimen, it added. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Centers for Disease Control and Prevention estimates more people get sick and die from drug-resistant germs than previously thought, the Washington Post reports.

According to the Associated Press, three universities and a healthcare institution are sharing a gift of $1 billion.

New rules seek to limit the type of scientific and medical research that can be used to guide public health regulations, the New York Times reports.

In Nature this week: FreeHi-C approach simulates Hi-C data from interacting genome fragments, and more.

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Sponsored by
BC Platforms

This webinar will discuss what it takes to begin realizing precision medicine in a comprehensive clinical infrastructure, with insights from the Colorado Center for Personalized Medicine (CCPM).